ReviewJournal of leukocyte biology2002
Role of CXCL1 in tumorigenesis of melanoma.
Review in Journal of leukocyte biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 1 synthesis or guideline pooled it, 308 citations in OpenAlex.
- Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis.Cancer biology & therapyPooled it
- The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity.Molecular medicine (Cambridge, Mass.) · 2026Article
- Lnk Governs chemokine-directed trafficking of CD8Molecular therapy. Oncology · 2026Article
- CXCL1 as a novel prognostic biomarker and immune regulator in colon adenocarcinoma.Discover oncology · 2026Article
- Towards a transcriptomic biomarker for the classification of melanocytic neoplasms.PLoS genetics · 2025Article
- Age-related and postmenopausal breast cancer progression and treatment management: The significance of pro-inflammatory cytokines and CXC chemokines.Genes & diseases · 2025Review
- The Evaluation of Potential Anticancer Activity of Meloxicam-In Vitro Study on Amelanotic and Melanotic Melanoma.International journal of molecular sciences · 2025Article
- Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors.Molecular pharmaceutics · 2025Article
- The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025Review
- Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.Life science alliance · 2025Article
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.European journal of immunology · 2024Review
- Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy.Nature communications · 2024Article
- Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma.Journal for immunotherapy of cancer · 2024Article
- Derivation of novel metabolic pathway score identifies alanine metabolism as a targetable influencer of TNF-alpha signaling.Heliyon · 2024Article
- ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived suppressor cells.Acta pharmaceutica Sinica. B · 2023Article
- TGFβ1 induces CXCL1 to promote stemness features in lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps.Cancer immunology, immunotherapy : CII · 2023Article
- The Activation of JAK/STAT3 Signaling and the Complement System Modulate Inflammation in the Primary Human Dermal Fibroblasts of PXE Patients.Biomedicines · 2023Article
- Multiplex Analysis of Cytokines and Chemokines in Persons Aging With or Without HIV.AIDS research and human retroviruses · 2023Article
- Comparative genomics analyses reveal sequence determinants underlying interspecies variations in injury-responsive enhancers.BMC genomics · 2023Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The CXC chemokine, CXCL1 (melanoma growth-stimulatory activity/growth-regulated protein alpha), plays a major role in inflammation, angiogenesis, tumorigenesis, and wound healing. Recently, chemokines have been extensively related to cellular transformation, tumor growth, homing, and metastasis. CXCL1 and its mouse homologue MIP-2 have been shown to be involved in the process of tumor formation. When chemokines such as CXCL1 and CXCL8 (IL-8) become disregulated so that they are chronically expressed, tissue damage, angiogenesis, and tumorigenesis can follow. This up-regulation of chemokines has been attributed to constitutive activation of NF-kappaB. The constitutive NF-kappaB activation is an emerging hallmark in various types of tumors including breast, colon, pancreatic, ovarian, as well as melanoma. Previous findings from our laboratory and other laboratories have demonstrated the role of endogenous activation of NF-kappaB in association with enhanced metastatic potential of malignant melanoma cells and suggest that targeting NF-kappaB may have potential therapeutic effects in clinical trials. An important step in this direction would be to delineate the important intracellular pathways and upstream kinases involved in up-regulation of NF-kappaB in melanoma cells. In this review, the signaling pathways involved in the disregulation of NF-kappaB and chemokine expression are discussed.
Indexed as
Identifiers
12101257PMC2668262W2096216039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.